Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Status:
Active, not recruiting
Trial end date:
2023-08-19
Target enrollment:
Participant gender:
Summary
This is a Phase 1 B feasibility trial with Galunsertib, a TGFβ inhibitor, in combination with
carboplatin/paclitaxel in patients with newly diagnosed, persistent or recurrent
carcinosarcoma of the uterus or ovary. The objective of the study is to determine whether
this drug combination is safe for this patient population and to see if it is effective in
shrinking cancers, keeping them from growing or helping patients live longer.